To identify the underlying molecular mechanisms of NAT2 and ATP7B-associated AT-DILI, we first evaluated the synergistic cytotoxicity between AT medications (INH and RIF) and Cu by measuring the viability of hepatocyte-derived HepG2 cells. The gene discussed is NAT2; the disease is ataxia telangiectasia.